Towards global consensus in the treatment of gastrointestinal stromal tumor

Expert Review of Anticancer Therapy

Volumn 10, Issue 2, 2010, Pages 221-232

  Reichardt, Peter ^a,b   Blay, Jean Yves ^c,d   Von Mehren, Margaret ^e  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b Sarcoma Center   (Germany)

^c UNIVERSITÉ LYON 1   (France)

^d EORTC   (France)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

Adjuvanteuropean society of medical oncology; Gastrointestinal stromal tumor; Guidelines; Imatinib; KIT; National comprehensive cancer network; Nilotinib; PDGFR ; Sarcoma; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

ADJUVANT THERAPY; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; METASTASIS; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RADIODIAGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT DURATION; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM METASTASIS;

EID: 76749154578     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.171     Document Type: Review

References (49)

1. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol. 3, 557-586 (2008).
2. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 64-67 (2009).
3. National Comprehensive Cancer Network. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 1.2009I). National Comprehensive Cancer Network, PA, USA (2009).
4. Blackstein ME, Blay JY, Corless C et al. Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment. Can. J. Gastroenterol. 20(3), 157-163 (2006).
5. Montemurro M, Dirnhofer S, Bornerc M et al. Diagnosis and treatment of GIST in Switzerland. Schweiz. Med. Forum 8, 544-549 (2008).
6. Nishida T, Hirota S, Yanagisawa A et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int. J. Clin. Oncol. 13(5), 416-430 (2008).
7. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23(23), 5357-5364 (2005). • Study reporting on PDGF receptor α-mutated gastrointestinal stromal tumor(GIST).
8. Taylor ML, Metcalfe DD. KIT signal transduction. Hematol. Oncol. Clin. North Am. 14(3), 517-535 (2000).
9. Bauer S, Hartmann JT, de Wit M et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int. J. Cancer 117(2), 316-325 (2005).
10. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. 24(15), 2325-2331 (2006).
11. Sym SJ, Ryu MH, Lee JL et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J. Surg. Oncol. 98(1), 27-33 (2008).
12. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann. Surg. 245(3), 347-352 (2007).
13. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic gist. Ann. Surg. 245(3), 341-346 (2007).
14. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J. Surg. Oncol. 93(4), 304-311 (2006).
15. Eisenberg BL, Harris J, Blanke CD et al. PhaseII trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J. Surg. Oncol. 99(1), 42-47 (2009).
16. DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669), 1097-1104 (2009). •• Presents final results of the large, randomized trial of adjuvant imatinib versus placebo for 12months; demonstrated benefit of imatinib in increasing disease-free survival in primary resected disease.
17. DeMatteo RP, Owzar K, Antonescu CR et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup Phase II trial ACOSOG Z9000. Program and Abstracts of the Gastrointestinal Cancers Symposium. Orlando, FL, USA, 25-27 January 2008 (Abstract 8).
18. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42(8), 1093-1103 (2006). •• Report of the benefit of high-dose imatinib in advanced GIST carrying an exon 9 mutation.
19. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized Phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J. Clin. Oncol. 25(9), 1107-1113 (2007). • Demonstration of the need to use imatinib continuously in advanceddisease.
20. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Twohundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 231(1), 51-58 (2000).
21. Hassan I, You YN, Shyyan R et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann. Surg. Oncol. 15(1), 52-59 (2008).
22. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br. J. Surg. 90(3), 332-339 (2003).
23. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 20(18), 3898-3905 (2002).
24. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized Phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26(4), 620-625 (2008). • Long-term follow-up of the Phase II trial of imatinib in GIST.
25. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002).
26. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626-632 (2008). • Phase III data on low- versus high-dose imatinib in advanced disease.
27. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440), 1127-1134 (2004). •• Phase III data on low- versus high-dose imatinib in advanced disease; demonstrated superiority of the high-dose arm for progression-free survival.
28. Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J. Gastrointest. Surg. 2(2), 151-155 (1998).
29. Bonvalot S, Eldweny H, Pechoux CL et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann. Surg. Oncol. 13(12), 1596-1603 (2006).
30. Hasegawa J, Kanda T, Hirota S et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int. J. Clin. Oncol. 12(3), 212-217 (2007).
31. Hohenberger P, Wardelmann E. [Surgical considerations for gastrointestinal stroma tumor]. Chirurg 77(1), 33-40 (2006).
32. Adenis A, Cassier P, Bui BN et al. Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial? J. Clin. Oncol. 26(Suppl.), (2008) (Abstract10522).
33. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann. Surg. Oncol. 11(5), 465-475 (2004).
34. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a PhaseI study. Lancet 358(9291), 1421-1423 (2001). • Dose escalation study demonstrating safety and efficacy of imatinib in GIST.
35. Technische Universität München. Csti571-bde43. Open-label trial of neoadjuvant imatinib mesylate (Glivec) in patients with locally advanced malignant gastrointestinal stromal tumors (GIST) expressing c-KIT or platelet-derived growth factor receptor-a. (NCT identifier: NCT00112632) (2009).
36. Radiation Therapy Oncology Group, National Cancer Institute (NCI), American College of Radiology Imaging Network, Eastern Cooperative Oncology Group. RTOG S-0132. A PhaseII trial of neoadjuvant/adjuvant STI-571 (Gleevec NSC #716051) for primary and recurrent operable malignant GIST expressing the KIT receptor tyrosine kinase (CD117). (NCT identifier: NCT00028002) (2009).
37. DeMatteo RP, Gold JS, Saran L et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112(3), 608-615 (2008).
38. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 23(2), 70-83 (2006). •• Reports on differences in risk of recurrence based on features of the primary tumor.
39. DeMatteo R, Owzar K, Maki R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Program and Abstract of the American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-5 June 2007 (Abstract 10079).
40. Shen L, Li J, Li J, Gong J, Wu A. Adjuvant post-surgery therapy with imatinib in intermediate or high-risk gastrointestinal stromal tumour (GIST) patients: interim analysis from a single centre comparison study. Ann. Oncol. 19(Suppl. 8), Viii 267. (2008) (Abstract870pd).
41. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33, 459-465 (2002).
42. Kang Y, Kang BW, Ryu M et al. A Phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors with c-KIT exon 11 mutation. Presented at: Gastrointestinal Cancers Symposium: Science and Multidisciplinary Management of GI Malignancies. San Francisco, CA, USA, 15-17 January 2009 (Abstract 95).
43. European Organization for Research and Treatment of Cancer, Italian Sarcoma Group, Federation Nationale des Centres de Lutte Contre le Cancer, Sarcomas GEdIe. EORTC 62024. Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery. (NCT identifier: NCT00103168) (2009).
44. Scandinavian Sarcoma Group. SSGXVIII/AIO. Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk of recurrence. (NCT identifier: NCT00116935) (2009).
45. Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol. 25(13), 1760-1764 (2007).
46. Le Cesne A, van Glabbekke M, Verweij J et al. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? J. Clin. Oncol. 24(18s), (2006) (Abstract 9510).
47. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25(13), 1753-1759 (2007). • Importance of changes in density in GIST tumors in identifying benefit to tyrosine kinase inhibitor therapy.
48. US FDA approves Gleevec to prevent recurrence of rare gastrointestinal cancer www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116997. htm(Accessed 30 September 2009)
49. Glivec: procedural steps taken and scientific information after the authorisation www.emea.europa.eu/humandocs/PDFs/EPAR/glivec/241801en8b. pdf(Accessed 30 September 2009)